Merck (MRK) shares closed up 3.3% to $127.63 on July 16. Earlier, U.S. regulators approved Lipfendra to become the first—and only—daily oral PCSK9 inhibitor tablet worldwide, which can reduce low-density lipoprotein cholesterol (LDL) by up to 60%, with no contraindication or allergy warning.
Lipfendra Approval Snapshot: First Oral PCSK9 Tablet, LDL Down 60%
According to the approval announcement, Lipfendra is the first and only daily oral PCSK9 inhibitor tablet globally. Its mechanism of action is to bind to the PCSK9 protein, and PCSK9 is involved in raising LDL cholesterol levels. Lipfendra has been proven to reduce LDL cholesterol by up to 60%, making it the most clearly described among PCSK9 inhibitor drugs in the package insert, with no contraindication or allergy warning.
In terms of usage restrictions, patients must take Lipfendra on an empty stomach, and wait 30 minutes after taking the medication before eating. It is currently approved only for adults. Merck launched Lipfendra at $315 per month, which is below injectable PCSK9 inhibitors ($500–$600 per month) and branded atorvastatin ($400–$600 per month).
MRK, AMGN, REGN, SNY Stocks: July 16 Approval-Day Price Moves
Based on the July 16, 2026 closing data, the four stocks directly related to this approval moved as follows:
MRK (Merck): Closed at $127.63, up 3.3%
AMGN (Amgen): Up 3.7%
REGN (Regeneron Pharmaceuticals): Up 2.2%
SNY (Sanofi): Up 1.2%
Amgen’s Repatha and Regeneron/Sanofi’s Praluent are both injectable PCSK9 inhibitors. Lipfendra’s oral form creates a direct competitive differentiation versus the injectables above.
Royal Bank of Canada Assessment: $5 Billion Sales Peak and Net Pricing Position Still to Be Seen
A Royal Bank of Canada Capital Markets analyst, Trung Huynh, in a client report, predicted that Lipfendra’s sales peak would reach $5 billion, higher than the market’s general expectation of $4 billion. The key basis is that the convenience of one pill per day will drive broad adoption by primary care physicians.
He said in the report: “Merck has signaled an aggressive, volume-driven pricing strategy, launching LIPFENDRA at $315 per month, which is a substantial discount versus injectable PCSK9 inhibitors ($500–$600 per month) and branded atorvastatin ($400–$600 per month).”
Huynh also cautioned that the insurance reimbursement rate for injectable PCSK9 inhibitors is about 60%, while generic statins under insurance coverage cost only $1 to $5 per month, making direct pricing comparisons complex. He said: “LIPFENDRA’s net price positioning relative to injectables will depend on Merck’s discount strategy, and that remains to be seen.”
FAQ
What is the market significance of Lipfendra’s approval?
Lipfendra is the first and only daily oral PCSK9 inhibitor tablet globally, priced at $315 per month, lower than injectable competing products; it has been proven to reduce LDL cholesterol by up to 60%, with no contraindication or allergy warning.
How did MRK stock perform after the July 16, 2026 approval?
Based on the July 16, 2026 closing data, MRK stock closed at $127.63, up 3.3%; on the same day, AMGN rose 3.7%, REGN rose 2.2%, and SNY rose 1.2%.
When will the cardiovascular outcomes research results for Lipfendra be released?
According to the original text, Merck is still conducting Lipfendra’s cardiovascular outcomes study, with results expected to be released in 2029. Competitors Praluent and Repatha have already been approved to reduce the risk of cardiovascular events, but Lipfendra has not yet obtained this indication.
